Pharsight

Aldara generic

Aldara is a topical cream owned by Bausch. Its active ingredient is imiquimod and it was first authorized for market use on 27 February, 1997. Aldara holds a total of 2 drug patents.

When will Aldara generic be available?

The generic version of Aldara is anticipated to be available after October 1, 2024. This timeline aligns with the expiration of Aldara's last patent, held on the Treatment for basal cell carcinoma

Aldara uses

Aldara cream is used for the treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc). The efficacy of Aldara can be credited to imiquimod, its active ingredient, which operates by inducing interferon and other cytokines.

Aldara patent expiration

Aldara holds two patents, with the last one due to expire on October 1, 2024, unlocking the possibility of Aldara generic. This patent is for 'Treatment for basal cell carcinoma.' Below are the details of the patent:

Aldara dosage

Want to ask something?